在脆弱的住院患者中评估免疫疗法的有效性
Charles Vincent Rajadurai1, Guillaume Gagnon2, Catherine Allard3
1Department of Medical Oncology, McGill University Health Centre (MUHC), McGill University, Montreal, QC H4A-3J1, Canada.
Current oncology (Toronto, Ont.)
|November 26, 2024
概括
免疫疗法在脆弱的住院癌症患者中效果较差,这些患者也会经历与免疫相关的重大不良事件. 基于表现状况和生物标志物的患者选择可能会改善结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 免疫疗法是一种关键的癌症治疗方法,但由于试验排除,其在住院,脆弱患者的疗效仍未得到充分研究.
- 这项研究调查了免疫治疗在这个脆弱的患者群体中的有效性.
研究的目的:
- 评估免疫治疗在脆弱的住院癌症患者的疗效和安全性.
- 确定预测该人群反应和生存的因素.
主要方法:
- 这是一项对49名在住院期间或住院后不久接受免疫治疗的患者进行的回顾性单中心研究.
- 通过客观应答率 (ORR),总生存率 (OS) 和无进展生存率 (PFS) 评估有效性.
- 分析与免疫相关的不良事件 (irAEs) 和预测因素,包括性能状态和血清生物标志物.
主要成果:
- 免疫疗法产生了30.6%的整体irAE率 (18.4%等级3-4).
- 脆弱患者的疗效较低:ORR 38.9%,PFS 2.8个月,OS 3.2个月.
- 糟糕的表现状态 (ECOG 3-4),低白蛋白和高的LDH预测了更糟糕的OS和PFS. 适应更多的治疗周期预测了更好的生存状况.
结论:
- 免疫疗法的有效性在脆弱的住院患者中受到损害,尽管有显著的irAEs.
- 性能状况,治疗周期数,血清白蛋白和LDH水平可以帮助选择可能受益于免疫治疗的患者.
相关概念视频
01:27Tumor Immunotherapy
480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
01:29Acute Respiratory Failure-V
123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123
01:51Vaccinations
44.1K
Overview
44.1K
01:28Pneumonia IV: Management
299
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
299
01:29Pulmonary Tuberculosis I
220
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
220